Achieving our mutual goals
Our goal is to be flexible, responsive, and honest within a partnership of equals designed to deliver value for both parties. Once a deal is done, our partners become long-term members of the team and always have the opportunity to fully participate in development decisions in relation to their products. Many partnerships are facilitated by a steering committee and shared governance.
Alliance management from the start
In addition to our business development professionals, AstraZeneca will also give you access to our scientific and commercial expertise from day one.
A dedicated Alliance Manager will be appointed from the start of the negotiation phase to ensure there is a seamless transition from the completion of a transaction to a full partnership.
Together, this partnering team will support you throughout the relationship, potential transaction and beyond; sharing your vision for your product or technology and championing the opportunity within AstraZeneca.
The role of R&D in business development
Our R&D strategy teams are tasked with sourcing innovation from both inside and outside the organisation. These teams have extensive links to the scientific, academic, and industry community, and will drive our partnering efforts in line with our overall R&D strategy to ensure appropriate fit with our portfolio.
Timelines and feedback
When a potential partner has submitted a proposal, we are committed to giving a prompt, tailored response within two weeks. For consistency, AstraZeneca follows a carefully defined partnering process involving four sequential gateways (or “Gates”) from evaluation through to contract signature.
We are open and transparent throughout the partnering process, sharing our scientific, regulatory and commercial insights and expertise at each stage. Even if our discussions do not proceed to the next gateway in the transaction process, we will strive to provide meaningful, honest and constructive feedback.
The 5R evaluation criteria
Both project evaluation and due diligence require stringent assessment criteria. To achieve this, we have created the “5 Rs” evaluation framework (Right target, Right tissue/exposure, Right safety, Right patients, Right commercial), providing a rigorous assessment and facilitating both speed and quality of execution. This evaluation takes place for all projects whether they are from partners or from our own laboratories, allowing us to take forward the most attractive opportunities regardless of source.
View our evaluation criteria
The 5 Rs ensure rapid, consistent feedback and effective due diligence
Right target |
|
Right tissue/exposure |
|
Right safety |
|
Right patients |
|
Right commercial |
|